Evidence map›Paper›PMID 40506287›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2025

Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis.

William T Harris, Elizabeth H Baker, Jennifer S Guimbellot, Joseph M Collaco, Michael S Schechter, Gabriela R Oates

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

William T HarrisUniversity of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA. Electronic address: wtharris@uabmc.edu.
Elizabeth H BakerUniversity of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
Jennifer S GuimbellotUniversity of Arkansas Medical Center, Little Rock, AR, USA.
Joseph M CollacoJohns Hopkins University, Baltimore, MD, USA.
Michael S SchechterChildren's Hospital of Richmond, Virginia Commonwealth University, Richmond, VA, USA.
Gabriela R OatesUniversity of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Funding

UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMIT GAGGAR · 2007 to 2026
$23.0M
NIDDK NIH HHS P30 DK072482
6 · The paper itself

Abstract

backgroundTobacco smoke exposure (TSE) is associated with diminished benefit of ivacaftor and tezacaftor/ivacaftor in people with CF (PwCF). This study assessed the association of TSE with clinical benefit from elexacaftor/tezacaftor/ivacaftor (E/T/I), focusing on lung function (ppFEV

methodsWe conducted a retrospective longitudinal analysis of data from the Cystic Fibrosis Foundation Patient Registry (2019-2021) on PwCF aged ≥ 12 years with documented prescription of E/T/I. TSE was defined by self-report of daily or weekly exposure, including living with a smoker or active smoking. Outcome measures were change in ppFEV

resultsIn 15,005 PwCF (mean age 27.7 years, 51.9 % F508del homozygous), TSE was associated with a 2.7 % lower ppFEV

conclusionE/T/I increases ppFEV

Indexed as

AminophenolsBenzodioxolesChloride Channel AgonistsCystic FibrosisIndolesPyrazolesPyridinesPyrrolidinesQuinolonesTobacco Smoke PollutionAdolescentAdultChildDrug CombinationsFemaleHumansAminophenolsBenzodioxolesChloride Channel AgonistsDrug Combinationselexacaftor, ivacaftor, tezacaftor drug combinationIndolesPyrazolesPyridinesPyrrolidinesQuinolinesQuinolonesTobacco Smoke PollutionCFTR modulatorCystic fibrosisElexacaftor/Tezacaftor/IvacaftorHealth disparitiesSecondhand smokeSmoke exposureTobacco

Identifiers

PMID40506287
PMCPMC12256006

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.